Digital ulcers in a cohort of 333 scleroderma patients;Ulcere digitali in una coorte di 333 pazienti sclerodermici

Reumatismo

Volumn 59, Issue 3, 2007, Pages 215-220

  Tiso, F ^a   Favaro, M ^a   Ciprian, L ^a   Cardarelli, S ^a   Rizzo, M ^a   Tonello, M ^a   Ruffatti, A ^a   Cozzi, Franco ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Bosentan; Digital ulcers; Systemic sclerosis; Treatment

Indexed keywords

ANTINUCLEAR ANTIBODY; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; PROSTANOID; SCL 70 ANTIBODY; AUTOANTIBODY; ENDOTHELIN RECEPTOR; NUCLEAR PROTEIN; PROSTAGLANDIN; SCL 70 ANTIGEN, HUMAN; SULFONAMIDE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DAY HOSPITAL; DRUG EFFICACY; FEMALE; FINGER ULCER; HAND DISEASE; HAND SURGERY; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH SERVICE; PREVALENCE; SCLERODERMA; SEX DIFFERENCE; SKIN ULCER; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE; ULCER; AGED; CENTROMERE; DIFFUSE SCLERODERMA; DRUG ANTAGONISM; FINGER; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; AUTOANTIBODIES; CENTROMERE; COHORT STUDIES; FEMALE; FINGERS; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PREVALENCE; PROSTAGLANDINS; RECEPTORS, ENDOTHELIN; SCLERODERMA, DIFFUSE; SKIN ULCER; SULFONAMIDES;

EID: 39549084998     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Chung L, Fiorentino D. Digital ulcers in patients with systemic sclerosis. Autoimmun Rev 2006; 5: 125-8.
2. Carvalho D, Savage CO, Black CM, Pearson GD. IgG antiendotelial cells autoantibodies from scleroderma patients induce leukocite adhesion to human vascular endothelial cells in vitro. J Clin Invest 1996; 97: 111-9.
3. Kaheleh MB. Vascular involvement in systemic sclerosis. Clin Exp Rheumatol 2004; 22 (Suppl 3): 19-23.
4. Hummers LK, Wigley FM. Management of Raynaud phenomenon and distal ischemic lesions in scleroderma. Rheum Dis Clin N Am 2003; 29: 293-313.
5. Yamamoto T, Katayama I, Nishioka K. Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis. J Rheumatol 1998; 25: 314-7.
6. Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R, et al. Circulating endothelin-1 levels in systemic sclerosis subsets-a marker of fibrosis or vascular dysfunction? J Rheumatol 1994; 21: 1838-44.
7. Fiori G, Amanzi L, Moggi Pignone A, Braschi F, Matucci-Cerinic M. The treatment of skin ulcers in patients with systemic sclerosis. Reumatismo 2004; 56: 225-34.
8. Wigley FM. Raynaud's phenomenon. N Engl J Med 2002; 47: 1001-8.
9. Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001; 44: 1841-7.
10. Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992; 19: 1407-14.
11. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA, et al. Intravenous iloprost infusion in patients with Raynaud's phenomenon secondary to systemic sclerosis. Ann Intern Med 1994; 120: 199-206.
12. Garcia Hernandez FJ, Ocana Medina C, Mateos Romero L, Molinillo Lòpez J, Arias Zambrano A, Gonzàlez Leòn R, et al. Iloprost for severe Raynaud's phenomenon ad ischemic ulcers related with systemic diseases. Med Clin 2004; 122: 501-4.
13. Vayssairat M. Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud's phenomenon. J Rheumatol 1996; 23: 1917-20.
14. Chung L, Fiorentino D. A pilot trial of treprostenil for the treatment and prevention of digital ulcers in patients with systemic sclerosis. J Am Acad Dermatol 2006; 54: 880-2.
15. Korn JH, Mayes M, Matucci-Cerinic M, Rainisio M, Pope J, Hachulla E, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50: 3985-93.
16. Bogoch ER, Gross DK. Surgery of the hand in patients with systemic sclerosis: outcomes and considerations. J Rheumatol 2005; 32: 642-8.
17. Le Roy EC, Black CM, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, et al. Scleroderma (systemic sclerosis): classification, subset and pathogenesis. J Rheumatol 1988; 15: 202-5.
18. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 italian patients. Medicine 2002; 81: 139-53.
19. Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosisa report from the EULAR Scleroderma Trials And Research (EUSTAR) data group. Ann Rheum Dis 2007; 66: 754-63.
20. Ostjic P, Damjanov N. Different clinical features in patients with limited and diffuse cutaneous systemic sclerosis. Clin Rheumatol 2006; 25: 453-7.
21. Ostjic P, Damjanov N, Pavlov-Dovlijanovic S, Radunovic G. Peripheral vasculopathy in patients with systemic sclerosis: difference in limited and diffuse subset of disease. Clin Hemorheol Microcirc 2004; 31: 281-5.
22. Nietert PJ, Mitchell HC, Bolster MB, Shaftman SR, Tilley BC, Silver RM. Racial variations in clinical and immunological manifestations of systemic sclerosis. J Rheumatol 2006; 33: 263-8.
23. Reville JD, Fishbach M, McNearney T, Friedman AW, Aguilar MB, Lisse J, et al. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001; 30: 332-46.
24. Wigley FM, Wise RA, Miller R, Needleman BW, Spence RJ. Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis. Arthritis Rheum 1992; 35: 688-93.
25. Poormoghim H, Lucas M, Fertig N, Medsger TA. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 2000; 43: 444-51.
26. Steen V, Medsger TA. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48: 516-22.
27. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005; 35: 35-42.
28. Channick RN, Simmoneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. The Lancet 2001; 358: 1119-23.
29. Rubin L, Badesch D, Barst LJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
30. Mc Laughlin VV. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur J Clin Invest 2006; 36 (Suppl 3): 10-5.
31. Cozzi F, Montisci R, Marotta H, Bobbo F, Durigon N, Ruscazio M et al. Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases. Eur J Clin Invest 2006; 36 (Suppl 3): 49-53.